Emergent BioSolutions Officer Receives 100,111 Restricted Stock Units

Simon C. Lowry, Senior Vice President of R&D and Chief Medical Officer of Emergent BioSolutions Inc., received a grant of 100,111 restricted stock units on April 29, 2026. The grant was approved by the Compensation Committee on March 2, 2026, and was contingent on stockholder approval of an amendment to the company's 2006 Stock Incentive Plan, which was obtained on April 29, 2026. The restricted stock units vest in three annual installments beginning on the anniversary of the approval date, assuming continued service with the company. Each unit represents the right to receive one share of common stock. Following this transaction, Lowry's total holdings increased to 177,914 shares. The transaction was reported on a Form 4 filing with an effective date of May 1, 2026.